Results 201 to 210 of about 2,579,690 (304)

Increased Risk of Subsequent Cancers in Patients With Sézary Syndrome

open access: yes
American Journal of Hematology, EarlyView.
Julia Nenonen   +3 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial. [PDF]

open access: yesJ Clin Oncol
Hauschild A   +25 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center. [PDF]

open access: yesBMC Cancer
De Mattia M   +11 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World Data. [PDF]

open access: yesCancers (Basel)
Blumenröther AK   +11 more
europepmc   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma. [PDF]

open access: yesJ Immunother Cancer
Yamada MM   +10 more
europepmc   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

open access: yesBMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy